GenCore version 5.1.3

OM protein - protein search, using sw model

Run on: January 16, 2003, 16:34:37 ; Search time 23.7857 Seconds
(without alignments)
28.011 Million cell updates/sec

Title: US-09-856-070-25
Perfect score: 23
Sequence: 1 MLRLQ 5

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: A_Geneseq_101002 *
1: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB	ID	Description
1	23	100.0	5	22	AAH82040	Human hepreceptor
2	23	100.0	11	22	AAH82039	Human hepreceptor
3	23	100.0	12	21	AAB17969	Integrin binding p
4	23	100.0	12	22	AAB82038	Human hepreceptor
5	23	100.0	12	23	AAU81119	Integrin antagonis
6	23	100.0	12	23	AAB72970	Integrin binding p
7	23	100.0	13	22	AAH82037	Human hepreceptor
8	23	100.0	15	21	AAB38185	Human secreted pro
9	23	100.0	34	22	AAB82020	Human hepreceptor
10	23	100.0	57	22	AAM87003	Human immune/haema
11	23	100.0	73	22	AAG06711	Human polypeptide
12	23	100.0	82	22	ABB10135	Human cDNA SEQ ID
13	23	100.0	109	21	AAG03845	Human secreted pro
14	23	100.0	111	22	ABG28299	Novel human diagno
15	23	100.0	114	21	AAG23000	Arabidopsis thalia
16	23	100.0	114	21	AAG47567	Arabidopsis thalia
17	23	100.0	115	21	AAG22999	Arabidopsis thalia
18	23	100.0	115	21	AAG47566	Arabidopsis thalia
19	23	100.0	116	22	AAG74592	Human colon cancer
20	23	100.0	124	21	AAG47540	Arabidopsis thalia
21	23	100.0	125	21	AAG47539	Arabidopsis thalia
22	23	100.0	134	22	AAU67629	Propionibacterium
23	23	100.0	150	23	ABP41710	Human ovarian anti
24	23	100.0	169	22	ABG09315	Novel human diagno
25	23	100.0	173	21	AAG22998	Arabidopsis thalia
26	23	100.0	173	21	AAG47565	Arabidopsis thalia
27	23	100.0	184	21	AAG47538	Arabidopsis thalia
28	23	100.0	185	21	AAG57352	Arabidopsis thalia
29	23	100.0	188	22	AAU66050	Propionibacterium
30	23	100.0	196	21	AAG57351	Arabidopsis thalia
31	23	100.0	199	23	ABP42172	Human ovarian anti
32	23	100.0	204	22	ABG19053	Novel human diagno
33	23	100.0	209	21	AAG03844	Human secreted pro
34	23	100.0	220	23	ABB47645	Listeria monocytog
35	23	100.0	222	21	AAG57350	Arabidopsis thalia
36	23	100.0	226	22	ABG08709	Novel human diagno
37	23	100.0	239	22	ABB11801	Human secreted pro
38	23	100.0	241	22	AAB94764	Human protein sequ
39	23	100.0	245	22	ABG09320	Novel human diagno
40	23	100.0	272	23	ABB48914	Listeria monocytog
41	23	100.0	278	22	AAB98003	S-adenosylmethioni
42	23	100.0	309	21	AAY73403	Human secreted pro
43	23	100.0	337	23	ABB91910	Herbicidally activ
44	23	100.0	347	22	ABG28300	Novel human diagno
45	23	100.0	448	22	ABB69117	Drosophila melanog

ALIGNMENTS

RESULT 1
AAB82040
ID AAB82040 standard; peptide; 5 AA.
XX
AC AAB82040;
XX
DT 13-JUN-2001 (first entry)
XX
DE Human hepreceptor domain A binding peptide Rupe2428.
XX
KW Human; hepreceptor; cytostatic; anti HIV; antibiotic;
KW nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW HIV related dementia.
XX
OS Homo sapiens.
XX
PN GB2354241-A.
XX
PD 21-MAR-2001.
XX
PF 17-SEP-1999; 99GB-0021881.
XX
PR 17-SEP-1999; 99GB-0021881.
XX
PA (HOLM/) HOLMS R D.
XX
PI Holms RD;
XX
DR WPI; 2001-293287/31.
XX
PT Novel regulatory or unfolding peptides of ezrin that binds to
PT Hepreceptor, useful for inducing immune response for treating
PT infectious diseases and cancer -

```
XX
PS   Claim 28; Page 47; 42pp; English
XX
CC   The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC   the structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present peptide binds to domain A of the
CC   hepreceptor (AAB82019).
XX
SQ   Sequence   5 AA;

  Query Match             100.0%;  Score 23;  DB 22;  Length 5;
  Best Local Similarity   100.0%;  Pred. No. 7.8e+05;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db       1 MLRLQ 5


RESULT 2
AAB82039
ID   AAB82039 standard; peptide; 11 AA.
XX
AC   AAB82039;
XX
DT   13-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain A binding peptide Rupe2232.
XX
KW   Human; hepreceptor; cytostatic; anti-HIV; antibiotic;
KW   nootropic; immune response inducer; ezrin, infectious diseases, cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified site   9
FT                   /note= "Optionally phosphorylated"
XX
PN   GB2354241-A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001-293287/31
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer
XX
PS   Claim 26; Page 37; 42pp; English.
XX
CC   The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC   the structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present peptide binds to domain A of the
CC   hepreceptor (AAB82019).
XX
SQ   Sequence   11 AA;

  Query Match             100.0%;  Score 23;  DB 22;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 19;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db       3 MLRLQ 7


RESULT 3
AAB17969
ID   AAB17969 standard; Peptide; 12 AA.
XX
AC   AAB17969;
XX
DT   31-OCT-2000  (first entry)
XX
DE   Integrin-binding peptide sequence SEQ ID NO:1081.
XX
KW   Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW   autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW   immunosuppressive; EPO; IPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW   MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW   cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW   vascular endothelial growth factor, matrix metalloproteinase;
KW   asthma; thrombosis; pharmaceutical.
XX
OS   Synthetic.
XX
PN   WO200024782-A2.
XX
PD   04-MAY-2000.
XX
PF   25-OCT-1999;   99WO-US25044.
XX
PR   23-OCT-1998;   98US-0105471.
PR   22-OCT-1999;   99US-0428082.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Feige U,  Liu C,  Cheetham J,  Boone TC;
XX
DR   WPI; 2000-350702/30.
XX
PT   Novel composition of matter comprising an Fc domain and
PT   pharmacologically active peptides, useful for treating cancer and
PT   autoimmune diseases
XX
PS   Claim 39; Page 592; 608pp; English.
XX
CC   The present invention describes composition of matter (I) comprising an
CC   Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC   (X1)a-F1-(X2)b,  where: F1 = an Fc domain; X1 and X2 = are each
CC   independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC   -(L1)c-P1-(L2)d-P2-(L3)e-P3, or -(L1)c-P1-(L2)d P2-(L3)e P3 (L4)f-P4
CC   where P1, P2, P3, and P4 = are each independently sequences of
CC   pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC   independently linkers; and a, b, c, d, e, and f = are each independently
CC   0 or 1, provided that at least 1 of a and b is 1. The composition can
CC   have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC   activities. DNAs, vectors and host cells from the present invention can
CC   be used for producing pharmaceutical compositions. The compositions are
CC   useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC   The use of an Fc domain (rather than a Fab domain) can provide a longer
CC   half life or incorporate functions such as Fc receptor binding, protein
CC   A binding, complement fixation, and possibly placental transfer. AAA69443
CC   to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC   sequences used in the exemplification of the present invention.
XX
SQ   Sequence   12 AA;

  Query Match             100.0%;  Score 23;  DB 21;  Length 12;
```

```
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db       6 MLRLQ 10


RESULT 4
AAB82038
ID   AAB82038 standard; peptide; 12 AA.
XX
AC   AAB82038;
XX
DT   13-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain A binding peptide Rupe2132.
XX
KW   Human; hepreceptor; cytostatic; anti HIV; antibiotic;
KW   nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   10
FT                   /note  "Optionally phosphorylated"
XX
PN   GB2354241 A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001 293287/31
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer  -
XX
PS   Claim 24; Page 36; 42pp; English.
XX
CC   The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC   the structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEPC (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present peptide binds to domain A of the
CC   hepreceptor (AAB82019).
XX
SQ   Sequence   12 AA;

  Query Match             100.0%;  Score 23;  DB 22;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db       4 MLRLQ 8


RESULT 5
AAU81119
ID   AAU81119 standard; Peptide; 12 AA.
XX
AC   AAU81119;
XX
DT   09-APR-2002  (first entry)
XX
DE   Integrin-antagonist peptide #26.
XX
KW   IgG Fc; anticoagulant; thrombolytic; cytostatic;
KW   antiinflammatory; immunosuppressive; osteopathic; antagonist;
KW   laminin; saw-scaled viper; echistatin; integrin; selectin; vinculin;
KW   platelet aggregation; angiogenesis; tumour; inflammation;
KW   autoimmune disease, rheumatoid arthritis; osteoporosis.
XX
OS   Synthetic.
XX
PN   WO200181377-A2.
XX
PD   01-NOV-2001.
XX
PF   23-APR-2001; 2001WO-US13069.
XX
PR   21-APR-2000; 2000US-198919P.
PR   03-MAY-2000; 2000US-201394P.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Feige U,  Kohno T,  Lacey DL,  Boone TC;
XX
DR   WPI; 2002-052025/08.
XX
PT   Composition comprising integrin or adhesion antagonistic peptide and
PT   vehicle, useful for treating or preventing platelet aggregation, has a
PT   longer half-life than free peptide  -
XX
PS   Claim 11; Page 19; 68pp; English.
XX
CC   The invention relates to a composition comprising an integrin/adhesion
CC   antagonistic peptide (I) and a vehicle e.g. IgG Fc. The peptides
CC   are based on laminin or saw-scaled viper echistatin and target integrin,
CC   selectin or vinculin.Also included are compounds of formula (Ia) and
CC   their multimers (X^1)_a-P^1-(X^2)_b where;
CC   P^1  = Fc domain;
CC   X^1 and X^2  = -(L^1)_c-P^1, (L^1)_c-P^1-(L^2)_d P^2,
CC   (L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3 or
CC   (L^1)_c-P^1-(L^2)_d-P^2-(L^3)_e-P^3-(L^4)_f-P^4;
CC   P^1-P^4  = same or different (I);
CC   L^1-L^4  = same or different linkers;
CC   a-f  = 0 or 1, provided at least one of a and b = 1,
CC   a nucleic acid that encodes (Ia), an expression vector containing the
CC   nucleic acid, host cells containing the vector, producing a
CC   pharmaceutically active compound (B) by covalently linking at least one
CC   Fc domain to at least one amino acid sequence of a selected randomized
CC   (r) and any of six laminin-related peptides (Ib). The compositions are
CC   used prophylactically and therapeutically in the same way as (I), e.g. to
CC   inhibit platelet aggregation or angiogenesis (tumours), or to treat
CC   inflammation and autoimmune diseases (e.g. rheumatoid arthritis) and many
CC   different forms of osteoporosis, also for diagnosis. Attaching the
CC   vehicle (especially Fc domain) to (I) increases the half-life (free (I)
CC   are normally degraded very quickly in vivo). The present sequence
CC   is an antagonist peptide of the invention.
XX
SQ   Sequence   12 AA;

  Query Match             100.0%;  Score 23;  DB 23;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db       6 MLRLQ 10


RESULT 6
ABB72970
ID   ABB72970 standard; Peptide; 12 AA.
```

```
XX
AC   ABB72970;
XX
DT   05-APR-2002  (first entry)
XX
DE   Integrin binding peptide SEQ ID NO:1081.
XX
KW   Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW   EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW   TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
KW   TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW   MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW   cytostatic; antirheumatic, antiarthritic, antidiabetic, ophthalmological;
KW   antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW   neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW   cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW   sleep disorder; neurological degenerative disease; anaemia;
KW   thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW   Fanconi's syndrome.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   WO200183525-A2.
XX
PD   08 NOV-2001.
XX
PF   02 MAY-2001; 2001WO-US14310.
XX
PR   03 MAY-2000; 2000US-0563286.
XX
PA   (AMGE-) AMGEN INC.
XX
PI   Feige U,  Liu C,  Cheetham JC,  Boone TC,  Gudas JM;
XX
DR   WPI; 2002-130313/17.
XX
PT   Novel vehicle-peptide molecule or its multimers useful for treating
PT   inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT   diabetic retinopathy, obesity, sleep disorders and infertility
XX
PS   Claim 39; Page 47; 176pp; English.
XX
CC   The present invention describes a vehicle peptide molecule (I) or its
CC   multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC   cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC   antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC   neuroprotective activities. (I) can be used as a therapeutic or
CC   prophylactic agent as well as for screening purposes. (I) is useful for
CC   diagnosing diseases characterised by dysfunction of their associated
CC   protein of interest, for identifying normal or abnormal proteins of
CC   interest, as a part of diagnostic kit to detect the presence of their
CC   proteins of interest in a biological sample. Additionally, (I) is useful
CC   for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC   rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC   infertility, and neurological degenerative diseases (I), comprising
CC   EPO-mimetic compounds are useful for treating disorders characterised by
CC   low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC   compounds are useful for treating conditions that involve an existing
CC   megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC   deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC   tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC   and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC   represent amino acid and nucleic acid sequences used in the
CC   exemplification of the present invention.
XX
SQ   Sequence   12 AA;

  Query Match             100.0%;  Score 23;  DB 23;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 21;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
             |||||
Db       6 MLRLQ 10


RESULT 7
AAB82037
ID   AAB82037 standard; peptide; 13 AA.
XX
AC   AAB82037;
XX
DT   13-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain A binding peptide Rupe2042.
XX
KW   Human; hepreceptor; cytostatic; anti-HIV; antibiotic;
KW   nootropic; immune response inducer, ezrin, infectious diseases; cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   11
FT                   /note= "Optionally phosphorylated"
XX
PN   GB2354241-A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001-293287/31.
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer
XX
PS   Claim 22; Page 36; 42pp; English.
XX
CC   The hepreceptor is a novel active site in human ezrin. Ezrin regulates
CC   the structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present peptide binds to domain A of the
CC   hepreceptor (AAB82019).
XX
SQ   Sequence   13 AA;

  Query Match             100.0%;  Score 23;  DB 22;  Length 13;
  Best Local Similarity   100.0%;  Pred. No. 24;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
             |||||
Db       5 MLRLQ 9


RESULT 8
AAB38185
ID   AAB38185 standard; Protein; 15 AA.
XX
AC   AAB38185;
XX
DT   30-JAN-2001  (first entry)
XX
DE   Human secreted protein sequence encoded by gene 9 SEQ ID NO:124.
```

```
XX
KW   Human; secreted protein; diagnosis; immunosuppressive; antiarthritic;
KW   antirheumatic; antiproliferative; cytostatic; cardiant; vasotropic;
KW   cerebroprotective; nootropic; neuroprotective; antibacterial; virucide;
KW   fungicide; ophthalmological; gene therapy; autoimmune disease; infection;
KW   hyperproliferative disorder; cardiovascular disorder; angiogenesis;
KW   cerebrovascular disorder, nervous system disorder, ocular disorder,
KW   wound healing; skin aging; food additive; preservative.
XX
OS   Homo sapiens.
XX
PN   WO200058468-A2.
XX
PD   05-OCT-2000.
XX
PF   22-MAR-2000; 2000WO-US07526.
XX
PR   26-MAR-1999;   99US-0126600.
PR   22-DEC-1999;   99US-0171559.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA, Ruben SM, Komatsoulis G;
XX
DR   WPI; 2000-611713/58.
XX
PT   Nucleic acids encoding human secreted proteins, used to prevent, treat,
PT   ameliorate, or diagnose conditions such as autoimmune disorders, skin
PT   disorders and cancer -
XX
PS   Disclosure; Page 367; 374pp; English.
XX
CC   The polynucleotide sequences given in AAC69390 to AAC69445 encode the
CC   human secreted proteins given in AAB38119 to AAB38165. AAB38166 to
CC   AAB38201 represent human secreted polypeptide sequences and proteins
CC   homologous to them, which are given in the exemplification of the present
CC   invention. Human secreted proteins have activities based on the tissues
CC   and cells the genes are expressed in. Example of activities include
CC   immunosuppressive, antiarthritic, antirheumatic, antiproliferative,
CC   cytostatic, cardiant, vasotropic, cerebroprotective, nootropic,
CC   neuroprotective, antibacterial, virucide, fungicide, and
CC   ophthalmological. The polynucleotides and polypeptides can be are used to
CC   prevent, treat or ameliorate a medical condition in e.g. humans, mice,
CC   rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC   in diagnosing a pathological condition or susceptibility to a
CC   pathological condition. Disorders which are diagnosed or treated include
CC   autoimmune diseases, hyperproliferative disorders, cardiovascular
CC   disorders, cerebrovascular disorders, angiogenesis, nervous system
CC   disorders, infections caused by bacteria, viruses and fungi and ocular
CC   disorders. The polypeptides can also be used to aid wound healing and
CC   epithelial cell proliferation, to prevent skin aging due to sunburn, to
CC   maintain organs before transplantation, for supporting cell culture of
CC   primary tissues, to regenerate tissues and in chemotaxis. The
CC   polypeptides can also be used as a food additive or preservative to
CC   increase or decrease storage capabilities. AAC69390 to AAC69398 and
CC   AAB38118 represent sequences used in the exemplification of the present
CC   invention.
XX
SQ   Sequence   15 AA;

  Query Match             100.0%;  Score 23;  DB 21;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 26;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db      10 MLRLQ 14


RESULT 9
AAB82020
ID   AAB82020 standard; peptide; 34 AA.
XX
AC   AAB82020;
XX
DT   13-JUN-2001  (first entry)
XX
DE   Human hepreceptor domain B.
XX
KW   Human; hepreceptor domain B; cytostatic; anti-HIV; antibiotic;
KW   nootropic; immune response inducer; ezrin; infectious diseases; cancer;
KW   HIV-related dementia.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Modified-site   14
FT                   /note= "Optionally phosphorylated"
XX
PN   GB2354241-A.
XX
PD   21-MAR-2001.
XX
PF   17-SEP-1999;   99GB-0021881.
XX
PR   17-SEP-1999;   99GB-0021881.
XX
PA   (HOLM/) HOLMS R D.
XX
PI   Holms RD;
XX
DR   WPI; 2001-293287/31.
XX
PT   Novel regulatory or unfolding peptides of ezrin that binds to
PT   Hepreceptor, useful for inducing immune response for treating
PT   infectious diseases and cancer -
XX
PS   Claim 5; Page 36; 42pp; English.
XX
CC   The present sequence is domain B of human hepreceptor of human ezrin. The
CC   hepreceptor is a novel active site in human ezrin. Ezrin regulates the
CC   structure of the cortical cytoskeleton to control cell surface
CC   topography. The present invention relates to peptides (see AAB82021 to
CC   AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see
CC   AAB82046). The hepreceptor binding peptides are useful for inducing
CC   immune response, and for treating infectious diseases, cancer and
CC   HIV-related dementia. The present sequence assembles into two
CC   anti-parallel helices with hepreceptor domain A (see AAB82019).
XX
SQ   Sequence   34 AA;

  Query Match             100.0%;  Score 23;  DB 22;  Length 34;
  Best Local Similarity   100.0%;  Pred. No. 57;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db       8 MLRLQ 12


RESULT 10
AAM87003
ID   AAM87003 standard; Protein; 57 AA.
XX
AC   AAM87003;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen SEQ ID NO:14596.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine, metastasis.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
```

XX
PD 09-AUG-2001
XX
PF 17-JAN-2001; 2001WO-US01354
XX
PR 31-JAN-2000; 2000US-0179065
PR 04-FEB-2000; 2000US-0180628
PR 24-FEB-2000; 2000US-0184664
PR 02-MAR-2000; 2000US-0186350
PR 16-MAR-2000; 2000US-0189874
PR 17-MAR-2000; 2000US-0190076.
PR 18-APR-2000; 2000US-0198123
PR 19-MAY-2000; 2000US-0205515
PR 07-JUN-2000; 2000US-0209467
PR 28-JUN-2000; 2000US-0214886
PR 30-JUN-2000; 2000US-0215135
PR 07-JUL-2000; 2000US-0216647
PR 07-JUL-2000; 2000US-0216880
PR 11-JUL-2000; 2000US-0217487
PR 11-JUL-2000; 2000US-0217496
PR 14-JUL-2000; 2000US-0218290
PR 26-JUL-2000; 2000US-0220963
PR 26-JUL-2000; 2000US-0220964
PR 14-AUG-2000; 2000US-0224518
PR 14-AUG-2000; 2000US-0224519
PR 14-AUG-2000; 2000US-0225213
PR 14-AUG-2000; 2000US-0225214
PR 14-AUG-2000; 2000US-0225266
PR 14-AUG-2000; 2000US-0225267
PR 14-AUG-2000; 2000US-0225268
PR 14-AUG-2000; 2000US-0225270
PR 14-AUG-2000; 2000US-0225447
PR 14-AUG-2000; 2000US-0225757
PR 14-AUG-2000; 2000US-0225758.
PR 14-AUG-2000; 2000US-0225759
PR 18-AUG-2000; 2000US-0226279
PR 22-AUG-2000; 2000US-0226881
PR 22-AUG-2000; 2000US-0226968
PR 22-AUG-2000; 2000US-0227182
PR 23-AUG-2000; 2000US-0227609
PR 30-AUG-2000; 2000US-0228924
PR 01-SEP-2000; 2000US-0229287
PR 01-SEP-2000; 2000US-0229343
PR 01-SEP-2000; 2000US-0229344
PR 01-SEP-2000; 2000US-0229345.
PR 05-SEP-2000; 2000US-0229509
PR 05-SEP-2000; 2000US-0229513
PR 06-SEP-2000; 2000US-0230437
PR 06-SEP-2000; 2000US-0230438
PR 08-SEP-2000; 2000US-0231242
PR 08-SEP-2000; 2000US-0231243
PR 08-SEP-2000; 2000US-0231244
PR 08-SEP-2000; 2000US-0231413
PR 08-SEP-2000; 2000US-0231414
PR 08-SEP-2000; 2000US-0232080
PR 08-SEP-2000; 2000US-0232081
PR 12-SEP-2000; 2000US-0231968.
PR 14-SEP-2000; 2000US-0232397
PR 14-SEP-2000; 2000US-0232398
PR 14-SEP-2000; 2000US-0232399
PR 14-SEP-2000; 2000US-0232400
PR 14-SEP-2000; 2000US-0232401.
PR 14-SEP-2000; 2000US-0233063
PR 14-SEP-2000; 2000US-0233064
PR 14-SEP-2000; 2000US-0233065
PR 21-SEP-2000; 2000US-0234227
PR 21-SEP-2000; 2000US-0234274
PR 25-SEP-2000; 2000US-0234997
PR 25-SEP-2000; 2000US-0234998.
PR 26-SEP-2000; 2000US-0235484.
PR 27-SEP-2000; 2000US-0235834.
PR 27-SEP-2000; 2000US-0235836.
PR 29-SEP-2000; 2000US-0236327.
PR 29-SEP-2000; 2000US-0236367.
PR 29-SEP-2000; 2000US-0236368.
PR 29-SEP-2000; 2000US-0236369.
PR 29-SEP-2000; 2000US-0236370.
PR 02-OCT-2000; 2000US-0236802.
PR 02-OCT-2000; 2000US-0237037.
PR 02-OCT-2000; 2000US-0237038.
PR 02-OCT-2000; 2000US-0237039.
PR 02-OCT-2000; 2000US-0237040.
PR 13-OCT-2000; 2000US-0239935.
PR 13-OCT-2000; 2000US-0239937.
PR 20-OCT-2000; 2000US-0240960.
PR 20-OCT-2000; 2000US-0241221.
PR 20-OCT-2000; 2000US-0241785.
PR 20-OCT-2000; 2000US-0241786.
PR 20-OCT-2000; 2000US-0241787.
PR 20-OCT-2000; 2000US-0241808.
PR 20-OCT-2000; 2000US-0241809.
PR 20-OCT-2000; 2000US-0241826.
PR 01-NOV-2000; 2000US-0244617.
PR 08-NOV-2000; 2000US-0246474.
PR 08-NOV-2000; 2000US-0246475.
PR 08-NOV-2000; 2000US-0246476.
PR 08-NOV-2000; 2000US-0246477.
PR 08-NOV-2000; 2000US-0246478.
PR 08-NOV-2000; 2000US-0246523.
PR 08-NOV-2000; 2000US-0246524.
PR 08-NOV-2000; 2000US-0246525.
PR 08-NOV-2000; 2000US-0246526
PR 08-NOV-2000; 2000US-0246527.
PR 08-NOV-2000; 2000US-0246528.
PR 08-NOV-2000; 2000US-0246532.
PR 08-NOV-2000; 2000US-0246609.
PR 08-NOV-2000; 2000US-0246610.
PR 08-NOV-2000; 2000US-0246611.
PR 08-NOV-2000; 2000US-0246613.
PR 17-NOV-2000; 2000US-0249207.
PR 17-NOV-2000; 2000US-0249208.
PR 17-NOV-2000; 2000US-0249209.
PR 17-NOV-2000; 2000US-0249210.
PR 17-NOV-2000; 2000US-0249211.
PR 17-NOV-2000; 2000US-0249212.
PR 17-NOV-2000; 2000US-0249213.
PR 17-NOV-2000; 2000US-0249214.
PR 17-NOV-2000; 2000US-0249215.
PR 17-NOV-2000; 2000US-0249216.
PR 17-NOV-2000; 2000US-0249217.
PR 17-NOV-2000; 2000US-0249218.
PR 17-NOV-2000; 2000US-0249244.
PR 17-NOV-2000; 2000US-0249245.
PR 17-NOV-2000; 2000US-0249264.
PR 17-NOV-2000; 2000US-0249265.
PR 17-NOV-2000; 2000US-0249297.
PR 17-NOV-2000; 2000US-0249299.
PR 17-NOV-2000; 2000US-0249300.
PR 01-DEC-2000; 2000US-0250160.
PR 01-DEC-2000; 2000US-0250391.
PR 05-DEC-2000; 2000US-0251030.
PR 05-DEC-2000; 2000US-0251388.
PR 05-DEC-2000; 2000US-0256719.
PR 06-DEC-2000; 2000US-0251479.
PR 08-DEC-2000; 2000US-0251856.
PR 08-DEC-2000; 2000US-0251868.
PR 08-DEC-2000; 2000US-0251869.
PR 08-DEC-2000; 2000US-0251989.
PR 08-DEC-2000; 2000US-0251990.
PR 11-DEC-2000; 2000US-0254097.
PR 05-JAN-2001; 2001US-0259678.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX

DR WPI; 2001-483426/52.
DR N-PSDB; AAK59784.
XX
PT Nucleic acids encoding human immune/haematopoietic antigen polypeptides, useful for preventing, diagnosing and/or treating cancers and metastasis -
XX
PS Claim 11; SEQ ID NO 14596; 3071pp + Sequence Listing; English.
XX
CC AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I) amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic activity, and can be used in gene therapy and vaccine production. (I) proteins and polynucleotides may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate (I) expression. For example, they may be used to treat disorders associated with decreased expression by rectifying mutations or deletions in a patient's genome that affect the activity of (I) by expressing inactive proteins or to supplement the patients own production of (I). Additionally, (I) polynucleotides may be used to produce the secreted (I), by inserting the nucleic acids into a host cell and culturing the cell to express the protein. (I) proteins and polynucleotides may be used to prevent, diagnose and treat immune/haematopoietic-related diseases, especially cancers and cancer metastases of haematopoietic-derived cells. AAK64703 to AAK87694 represent human immune/haematopoietic antigen genomic sequences from the present invention. AAK54942 to AAK54950 and AAM82169 represent sequences used in the exemplification of the present invention.
XX
SQ Sequence 57 AA;

Query Match 100.0%; Score 23; DB 22; Length 57;
Best Local Similarity 100.0%; Pred. No. 95;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLRLQ 5
|||||
Db 7 MLRLQ 11

RESULT 11
AA006711
ID AA006711 standard; Protein; 73 AA.
XX
AC AA006711;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 20603.
XX
KW Human; cytokine; cell proliferation; cell differentiation; gene therapy; vaccine; peptide therapy; stem cell growth factor; haematopoiesis; tissue growth factor; immunomodulatory; cancer; leukaemia; nervous system disorders; arthritis; inflammation.
XX
OS Homo sapiens.
XX
PN WO200164835-A2.
XX
PD 07-SEP-2001.
XX
PF 26-FEB-2001; 2001WO-US04927.
XX
PR 28-FEB-2000; 2000US-0515126.
PR 18-MAY-2000; 2000US-0577409.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Ormanac RT;
XX
DR WPI; 2001-514848/56.
DR N-PSDB; AAI86642.
XX
PT Isolated nucleic acids and polypeptides, useful for preventing
PT diagnosing and treating e.g. leukaemia, inflammation and immune
PT disorders -
XX
PS Claim 20; SEQ ID NO 20603; 1399pp + Sequence Listing; English.
XX
CC The invention relates to human polynucleotides (AA179941-AA193841) and the encoded proteins (AA000010-AA013910) that exhibit activity elating to cytokine, cell proliferation or cell differentiation or which may induce production of other cytokines in other cell populations. The polynucleotides and polypeptides are useful in gene therapy, vaccines or peptide therapy. The polypeptides have various cytokine like activities, e.g. stem cell growth factor activity, haematopoiesis regulating activity, tissue growth factor activity, immunomodulatory activity and activin/inhibin activity and may be useful in the diagnosis and/or treatment of cancer, leukaemia, nervous system disorders, arthritis and inflammation.
CC Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 73 AA;

Query Match 100.0%; Score 23; DB 22; Length 73;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLRLQ 5
|||||
Db 68 MLRLQ 72

RESULT 12
ABB10135
ID ABB10135 standard; Protein; 82 AA.
XX
AC ABB10135;
XX
DT 10-JAN-2002 (first entry)
XX
DE Human cDNA SEQ ID NO: 443.
XX
KW Human; gene therapy; neural disorder; immune system disorder; muscular disorder, reproductive disorder, gastrointestinal disorder; pulmonary disorder; cardiovascular disorder; renal disorder; proliferative disorder; inflammation.
XX
OS Homo sapiens.
XX
PN WO200154474-A2
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US01349.
XX
PR 31-JAN-2000; 2000US-179065P.
PR 04-FEB-2000; 2000US-180628P.
PR 24-FEB-2000; 2000US-184664P.
PR 02-MAR-2000; 2000US-186350P.
PR 16-MAR-2000; 2000US-189874P.
PR 17-MAR-2000; 2000US-190076P.
PR 18-APR-2000; 2000US-198123P.
PR 19-MAY-2000; 2000US-205515P.
PR 07-JUN-2000; 2000US-209467P.
PR 28-JUN-2000; 2000US-214886P.
PR 30-JUN-2000; 2000US-215135P.
PR 07-JUL-2000; 2000US-216647P.
PR 07-JUL-2000; 2000US-216880P.
PR 11-JUL-2000; 2000US-217487P.
PR 11-JUL-2000; 2000US-217496P.
PR 14-JUL-2000; 2000US-218290P.
PR 26-JUL-2000; 2000US-220963P.
PR 26-JUL-2000; 2000US-220964P.
PR 14-AUG-2000; 2000US-224518P.
PR 14-AUG-2000; 2000US-224519P.

PR 14-AUG-2000; 2000US-225213P.
PR 14-AUG-2000; 2000US-225214P.
PR 14-AUG-2000; 2000US-225266P.
PR 14-AUG-2000; 2000US-225267P.
PR 14-AUG-2000; 2000US-225268P.
PR 14-AUG-2000; 2000US-225270P.
PR 14-AUG-2000; 2000US-225447P.
PR 14-AUG-2000; 2000US-225757P.
PR 14-AUG-2000; 2000US-225758P.
PR 14-AUG-2000; 2000US-225759P.
PR 18-AUG-2000; 2000US-226279P.
PR 22-AUG-2000; 2000US-226681P.
PR 22-AUG-2000; 2000US-226868P.
PR 22-AUG-2000; 2000US-227182P.
PR 23-AUG-2000; 2000US-227809P.
PR 30-AUG-2000; 2000US-228824P.
PR 01-SEP-2000; 2000US-229287P.
PR 01-SEP-2000; 2000US-229343P.
PR 01-SEP-2000; 2000US-229344P.
PR 01-SEP-2000; 2000US-229445P.
PR 05-SEP-2000; 2000US-229509P.
PR 05-SEP-2000; 2000US-229513P.
PR 06-SEP-2000; 2000US-230437P.
PR 06-SEP-2000; 2000US-230438P.
PR 08-SEP-2000; 2000US-231242P.
PR 08-SEP-2000; 2000US-231243P.
PR 08-SEP-2000; 2000US-231244P.
PR 08-SEP-2000; 2000US-231413P.
PR 08-SEP-2000; 2000US-231414P.
PR 08-SEP-2000; 2000US-232089P.
PR 08-SEP-2000; 2000US-232982P.
PR 12-SEP-2000; 2000US-233968P.
PR 14-SEP-2000; 2000US-232397P.
PR 14-SEP-2000; 2000US-232398P.
PR 14-SEP-2000; 2000US-232399P.
PR 14-SEP-2000; 2000US-232400P.
PR 14-SEP-2000; 2000US-232401P.
PR 14-SEP-2000; 2000US-233063P.
PR 14-SEP-2000; 2000US-233064P.
PR 14-SEP-2000; 2000US-233065P.
PR 21-SEP-2000; 2000US-234223P.
PR 21-SEP-2000; 2000US-234224P.
PR 25-SEP-2000; 2000US-234997P.
PR 25-SEP-2000; 2000US-234998P.
PR 26-SEP-2000; 2000US-235484P.
PR 27-SEP-2000; 2000US-235834P.
PR 27-SEP-2000; 2000US-235835P.
PR 29-SEP-2000; 2000US-236327P.
PR 29-SEP-2000; 2000US-236367P.
PR 29-SEP-2000; 2000US-236368P.
PR 29-SEP-2000; 2000US-236369P.
PR 29-SEP-2000; 2000US-236370P.
PR 02-OCT-2000; 2000US-236802P.
PR 02-OCT-2000; 2000US-237037P.
PR 02-OCT-2000; 2000US-237038P.
PR 02-OCT-2000; 2000US-237039P.
PR 02-OCT-2000; 2000US-237040P.
PR 13-OCT-2000; 2000US-239935P.
PR 13-OCT-2000; 2000US-239937P.
PR 20-OCT-2000; 2000US-240960P.
PR 20-OCT-2000; 2000US-241221P.
PR 20-OCT-2000; 2000US-241785P.
PR 20-OCT-2000; 2000US-241786P.
PR 20-OCT-2000; 2000US-241787P.
PR 20-OCT-2000; 2000US-241808P.
PR 20-OCT-2000; 2000US-241809P.
PR 20-OCT-2000; 2000US-241826P.
PR 01-NOV-2000; 2000US-244617P.
PR 08-NOV-2000; 2000US-246474P.
PR 08-NOV-2000; 2000US-246475P.
PR 08-NOV-2000; 2000US-246476P.
PR 08-NOV-2000; 2000US-246477P.
PR 08-NOV-2000; 2000US-246478P.

PR 08-NOV-2000; 2000US-246523P.
PR 08-NOV-2000; 2000US-246524P.
PR 08-NOV-2000; 2000US-246525P.
PR 08-NOV-2000; 2000US-246526P.
PR 08-NOV-2000; 2000US-246527P.
PR 08-NOV-2000; 2000US-246528P.
PR 08-NOV-2000; 2000US-246532P.
PR 08-NOV-2000; 2000US-246609P.
PR 08-NOV-2000; 2000US-246610P.
PR 08-NOV-2000; 2000US-246611P.
PR 08-NOV-2000; 2000US-246613P.
PR 17-NOV-2000; 2000US-249207P.
PR 17-NOV-2000; 2000US-249208P.
PR 17-NOV-2000; 2000US-249209P.
PR 17-NOV-2000; 2000US-249210P.
PR 17-NOV-2000; 2000US-249211P.
PR 17-NOV-2000; 2000US-249212P.
PR 17-NOV-2000; 2000US-249213P.
PR 17-NOV-2000; 2000US-249214P.
PR 17-NOV-2000; 2000US-249215P.
PR 17-NOV-2000; 2000US-249216P.
PR 17-NOV-2000; 2000US-249217P.
PR 17-NOV-2000; 2000US-249218P.
PR 17-NOV-2000; 2000US-249244P.
PR 17-NOV-2000; 2000US-249245P.
PR 17-NOV-2000; 2000US-249264P.
PR 17-NOV-2000; 2000US-249265P.
PR 17-NOV-2000; 2000US-249297P.
PR 17-NOV-2000; 2000US-249299P.
PR 17-NOV-2000; 2000US-249300P.
PR 01-DEC-2000; 2000US-250160P.
PR 01-DEC-2000; 2000US-250391P.
PR 05-DEC-2000; 2000US-251030P.
PR 05-DEC-2000; 2000US-251988P.
PR 05-DEC-2000; 2000US-256719P.
PR 06-DEC-2000; 2000US-251479P.
PR 08-DEC-2000; 2000US-251856P.
PR 08-DEC-2000; 2000US-251868P.
PR 08-DEC-2000; 2000US-251869P.
PR 08-DEC-2000; 2000US-251989P.
PR 08-DEC-2000; 2000US-251990P.
PR 11-DEC-2000; 2000US-254097P.
PR 05-JAN-2001; 2001US-259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476161/51.
DR N-PSDB; ABA06357.
XX
PT Isolated nucleic acid molecule encoding an inflammation associated
PT polypeptide is used in preventing, treating or ameliorating a medical
PT condition -
XX
PS Claim 11; SEQ ID NO 443; 859pp + Sequence Listing; English.
XX
CC The present invention provides human cDNAs, proteins and related genomic
CC DNAs. These can be used in the treatment of neural, immune system,
CC muscular, reproductive, gastrointestinal, pulmonary, cardiovascular,
CC renal and proliferative disorders and inflammation. The present sequence
CC is a protein of the invention.
XX
SQ Sequence 82 AA;

Query Match 100.0%; Score 23; DB 22; Length 82;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLRLQ 5
|||||
Db 34 MLRLQ 38

```
RESULT 13
AAG03845
ID   AAG03845 standard; Protein; 109 AA.
XX
AC   AAG03845;
XX
DT   06-OCT-2000  (first entry)
XX
DE   Human secreted protein, SEQ ID NO: 7926.
XX
KW   Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW   gene therapy; chromosome mapping.
XX
OS   Homo sapiens.
XX
PN   EP1033401-A2.
XX
PD   06-SEP-2000.
XX
PF   21-FEB-2000; 2000EP-0200610
XX
PR   26-FEB-1999;   99US-0122487.
XX
PA   (GEST ) GENSET.
XX
PI   Dumas Milne Edwards J, Duclert A, Giordano J;
XX
DR   WPI; 2000-500381/45.
DR   N-PSDB; AAC03851.
XX
PT   New nucleic acid that is a 5' expressed sequence tag (5' EST) for
PT   obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
PT   diagnostic, forensic, gene therapy and chromosome mapping procedures -
XX
PS   Claim 13; SEQ ID 7926; 71pp + CD-ROM; English
XX
CC   The present sequence is a polypeptide encoded by one of a large number
CC   of 5' ESTs derived from mRNAs encoding secreted proteins. The 5' ESTs
CC   were prepared from total human RNAs or polyA+ RNAs derived from 30
CC   different tissues. EST sequences usually correspond mainly to the 3'
CC   untranslated region (UTR) of the mRNA because they are often obtained
CC   from oligo-dT primed cDNA libraries. Such ESTs are not well suited for
CC   isolating cDNA sequences derived from the 5' ends of mRNAs and even in
CC   those cases where longer cDNA sequences have been obtained, the full 5'
CC   UTR is rarely included. 5' ESTs are derived from mRNAs with intact 5'
CC   ends and can therefore be used to obtain full length cDNAs and genomic
CC   DNAs. 5' ESTs are also used in diagnostic, forensic, gene therapy and
CC   chromosome mapping procedures. They are used to obtain upstream
CC   regulatory sequences and to design expression and secretion vectors.
XX
SQ   Sequence   109 AA;

  Query Match             100.0%;  Score 23;  DB 21;  Length 109;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db      21 MLRLQ 25


RESULT 14
ABG28299
ID   ABG28299 standard; Protein; 111 AA.
XX
AC   ABG28299;
XX
DT   18-FEB-2002  (first entry)
XX
DE   Novel human diagnostic protein #28299.
XX
KW   Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW   food supplement; medical imaging; diagnostic; genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200175067-A2.
XX
PD   11-OCT-2001.
XX
PF   30-MAR-2001; 2001WO-US08631.
XX
PR   31-MAR-2000; 2000US-0540217.
PR   23-AUG-2000; 2000US-0649167.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Drmanac RT, Liu C, Tang YT;
XX
DR   WPI; 2001-639362/73.
DR   N-PSDB; AAS92486.
XX
PT   New isolated polynucleotide and encoded polypeptides, useful in
PT   diagnostics, forensics, gene mapping, identification of mutations
PT   responsible for genetic disorders or other traits and to assess
PT   biodiversity -
XX
PS   Claim 20; SEQ ID No 58658; 103pp; English.
XX
CC   The invention relates to isolated polynucleotide (I) and
CC   polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC   polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC   and gene mapping, and in recombinant production of (II). The
CC   polynucleotides are also used in diagnostics as expressed sequence tags
CC   for identifying expressed genes. (I) is useful in gene therapy techniques
CC   to restore normal activity of (II) or to treat disease states involving
CC   (II). (II) is useful for generating antibodies against it, detecting or
CC   quantitating a polypeptide in tissue, as molecular weight markers and as
CC   a food supplement. (II) and its binding partners are useful in medical
CC   imaging of sites expressing (II). (I) and (II) are useful for treating
CC   disorders involving aberrant protein expression or biological activity.
CC   The polypeptide and polynucleotide sequences have applications in
CC   diagnostics, forensics, gene mapping, identification of mutations
CC   responsible for genetic disorders or other traits to assess biodiversity
CC   and to produce other types of data and products dependent on DNA and
CC   amino acid sequences. ABG00010-ABG00377 represent novel human
CC   diagnostic amino acid sequences of the invention.
CC   Note: The sequence data for this patent did not appear in the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ   Sequence   111 AA;

  Query Match             100.0%;  Score 23;  DB 22;  Length 111;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy       1 MLRLQ 5
           |||||
Db       7 MLRLQ 11


RESULT 15
AAG23000
ID   AAG23000 standard; Protein; 114 AA.
XX
AC   AAG23000;
XX
DT   17-OCT-2000  (first entry)
XX
DE   Arabidopsis thaliana protein fragment SEQ ID No. 26142.
XX
KW   Protein identification; signal transduction pathway; metabolic pathway;
KW   hybridisation assay; genetic mapping; gene expression control; promoter;
KW   termination sequence.
```

XX
OS Arabidopsis thaliana
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486
PR 06-MAY-1999; 99US-0132487
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139464.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139764.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140354.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.

PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 100.0%; Score 23; DB 21; Length 114;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MLRLQ 5
|||||
Db 32 MLRLQ 36

Search completed: January 16, 2003, 16:49:16
Job time : 24.7857 secs